SEARCH:
Signup to create an account
test
Lone Star Opposes SWS Group's Merger Plans

SWS Group Inc. (NYSE: SWS), a diversified financial services holding company, recently announced a merger agreement with Hilltop Holdings Inc. (NYSE: HTH) in a cash and stock transaction amounting to 0.2469 shares of HTH and $1.94 in cash for each share of SWS.

test
JANA Partners Tightens the Leash on PetSmart

PetSmart Inc. (NASDAQ: PETM), a leading retailer of pets and pet-related goods and services, recently hired JPMorgan Chase to analyze the possibility of a leveraged share buyback, according to Reuters reports.


test
HighTech Set To Disrupt the BioTech Industry

In a new world of high tech discoveries, Silicon Valley is creating advances that are now being used to revolutionize the biotech industry.

Recent 8K Filings
STAGE STORES INC
LAS VEGAS SANDS CORP
ALEXCO RESOURCE CORP
GLOBAL MEDICAL REIT INC.
SAASMAX, INC.
TEAM HEALTH HOLDINGS INC.
ZOOM TECHNOLOGIES INC
BANCO SANTANDER CHILE
BRINKER INTERNATIONAL INC

Recent Insider Filings
AKORN INC (KAPOOR JOHN N)
INVENTERGY GLOBAL, INC. (HUANG STEPHEN B)
CYTOMEDIX INC (SHALLCROSS STEVEN A)
VACCINOGEN INC (ROBINSON JEANNE M.)
VACCINOGEN INC (ROBINSON JEANNE M.)
SCRIPPS NETWORKS INTERACTIVE, INC. (SCRIPPS CYNTHIA J)
MERRIMACK PHARMACEUTICALS INC (SINSKEY ANTHONY J)
FIRST COMMUNITY BANCSHARES INC /NV/ (MILLS GARY R)
FIRST COMMUNITY BANCSHARES INC /NV/ (MILLS GARY R)



Executive Interview
Quantum Energy, Inc. (OTC: QEGY)
In this episode we speak with Mr. Russell Smith, EVP of Public Affairs for Quantum Energy, about the company's plans to build 21st Century Energy Centers in the Bakken oil fields.


Executive Interview
Theralase Technologies (OTC: TLTFF)
In this episode we will be talking to Mr. Roger Dumoulin-White, President & CEO of Theralase Technologies. Theralase designs, manufactures and markets patented, super-pulsed laser technology used in eliminating pain and destroying cancer.


Executive Interview
Galectin Therapeutics (NASDAQ: GALT)
In this SECFilings.com Executive Interview we speak with Mr. Jim Czirr, Executive Chairman of Galectin Therapeutics.



The page you have requested does not exist. We have recently renovated the website, so links from old email alerts may not work as intended. We thank you for your patience.